Sökresultat
FDA godkÀnner KesimptaŸ (ofatumumab), en targeted B-cell therapy för patienter med MS
…current evidence. Accessed August 12, 2020. http://ms-coalition.org/the-use-of-disease-modifying-therapies-in-multiple-sclerosis-updated/ 6. Cree BA, Mares J, Hartung HP. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Curr Opin Neurol. 2019;32(3):365-377. 7. Lehmann-Horn K, Kronsbein HC, Weber MS. Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther Adv Neuro…
Dosering av natalizumab var sjÀtte vecka istÀllet för var fjÀrde för personer med skovvis förlöpande multipel skleros
…00013 (Q6W), with 97.9 percent of patients in the Q4W arm remaining relapse-free compared to 97.2 percent of patients in the Q6W arm. The safety findings in the NOVA study were consistent with the known safety profile of IV natalizumab, and the incidence of serious adverse events (SAEs) and adverse events (AEs) was similar between the two treatment arms. AEs leading to discontinuation of study treatment were reported by four of 250 (2%) Q6W partic…
Ultomiris godkÀnd i USA för vuxna med Myastenia gravis
…e secondary endpoints evaluating improvement in disease-related and quality-of-life measures. Patients who completed the randomised control period were eligible to continue into an open-label extension period evaluating the safety and efficacy of Ultomiris, which is ongoing. Ultomiris Ultomiris (ravulizumab-cwvz), the first and only long-acting C5 complement inhibitor, offers immediate, complete and sustained complement inhibition. The medication…
Johns Hopkins forskare utvecklar flytande biomarkör för upptÀckt av degenerativa sjukdomar
…ion submitted by The Johns Hopkins University that covers the use of TDP-43-associated cryptic exon-derived neoepitopes as biomarkers. Traynor holds patents on the clinical testing and therapeutic intervention for the hexanucleotide repeat expansion of C9orf72. Bartlett is an employee and shareholder of Biogen. At the time of the study, Raitcheva was an employee and shareholder of Biogen. The other study authors do not have financial or conflict-o…
Ultomiris godkÀnd vid Myastenia Gravis
…der symptoms. Ultomiris (ravulizumab) has been approved in Europe as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. This decision marks the first and only approval for a long-acting C5 complement inhibitor for the treatment of gMG in Europe. gMG is a rare, debilitating, chronic, autoimmune neuromuscular disease that leads to a…